Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Therapies of the state

Nature Biotechnology volume 32, pages 736–741 (2014)Cite this article

Subjects

What can governmental agencies do to lower the risk of cell therapies and the enterprises commercializing them?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Global tissue engineering market.
Figure 2: Timeline of seminal events in cell therapy R&D.

References

  1. Giebel, L. Stem cells—a hard sell to investors. Nat. Biotechnol. 23, 798–800 (2005).

    Article  CAS  Google Scholar 

  2. Alliance for Regenerative Medicine. 2014 Regenerative Medicine Annual Industry Report (2014).

Download references

Author information

Authors and Affiliations

  1. Beth Schachter is a freelance writer based in New York.,

    Beth Schachter

Authors
  1. Beth Schachter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schachter, B. Therapies of the state. Nat Biotechnol 32, 736–741 (2014). https://doi.org/10.1038/nbt.2984

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2984

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research